Long noncoding RNAs and Alzheimer's disease

• Published in: Clinical interventions in aging Vol. 11; pp. 867 - 872
• Main Authors: Luo, Qiong, Chen, Yinghui
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2016; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Aged; Alzheimer Disease - genetics; Alzheimer's disease; Amyloid beta-Peptides - genetics; Amyloid β peptide，β-site amyloid precursor protein cleaving enzyme-1; Apoptosis; Cell cycle; Development and progression; Enzymes; Gene Expression; Genetic aspects; Humans; lncRNA; ncRNAs; Neuroblastoma; Pathogenesis; Peptides; Proteins; Review; RNA polymerase; RNA, Long Noncoding - genetics; RNA, Untranslated - genetics; United States; BACE1; BC200; lncRNA; Alzheimer’s disease; BACE1-AS; amyloid β peptide; ncRNAs
• ISSN: 1178-1998; 1176-9092; 1178-1998
• DOI: 10.2147/CIA.S107037

Long noncoding RNAs (lncRNAs) are typically defined as transcripts longer than 200 nucleotides. lncRNAs can regulate gene expression at epigenetic, transcriptional, and posttranscriptional levels. Recent studies have shown that lncRNAs are involved in many neurological diseases such as epilepsy, neurodegenerative conditions, and genetic disorders. Alzheimer's disease is a neurodegenerative disease, which accounts for >80% of dementia in elderly subjects. In this review, we will highlight recent studies investigating the role of lncRNAs in Alzheimer's disease and focus on some specific lncRNAs that may underlie Alzheimer's disease pathophysiology and therefore could be potential therapeutic targets.